Based on the Tenax Therapeutics Inc stock forecast from 2 analysts, the average analyst target price for Tenax Therapeutics Inc is USD 18.00 over the next 12 months. Tenax Therapeutics Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Tenax Therapeutics Inc is Bearish, which is based on 1 positive signals and 4 negative signals. At the last closing, Tenax Therapeutics Inc’s stock price was USD 5.56. Tenax Therapeutics Inc’s stock price has changed by -4.14% over the past week, -10.18% over the past month and +47.87% over the last year.
No recent analyst target price found for Tenax Therapeutics Inc
No recent average analyst rating found for Tenax Therapeutics Inc
Company Overview Tenax Therapeutics Inc
Tenax Therapeutics, Inc. develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is based in Chapel Hill, North Carolina. Read Less
Tenax Therapeutics, Inc. develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical...Read More
Frequently Asked Questions About Tenax Therapeutics Inc (TENX) Stock
Based on ratings from 2 analysts Tenax Therapeutics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 3 buy, sell and hold ratings.
Unfortunately we do not have enough data on TENX's stock to indicate if its a good dividend stock.
Based on targets from 2 analysts, the average taret price for TENX is USD 18.00 over the next 12 months. The maximum analyst target price is USD 20 while the minimum anlayst target price is USD 16.
Unfortunately we do not have enough data on TENX's stock to indicate if its overvalued.
The last closing price of TENX's stock was USD 5.56.
The most recent market capitalization for TENX is USD 0.03B.
Based on targets from 2 analysts, the average taret price for TENX is projected at USD 18.00 over the next 12 months.
This means that TENX's stock price may go up by +223.74% over the next 12 months.
We can't find any ETFs which contains Tenax Therapeutics Inc's stock.
As per our most recent records Tenax Therapeutics Inc has 5 Employees.
Tenax Therapeutics Inc's registered address is 101 Glen Lennox Drive, Chapel Hill, NC, United States, 27517.
You can get more information about it from Tenax Therapeutics Inc's website at https://www.tenaxthera.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Underpriced compared to book value
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
What not to like
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Frequently Asked Questions About Tenax Therapeutics Inc (TENX) Stock
Based on ratings from 2 analysts Tenax Therapeutics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 3 buy, sell and hold ratings.
Unfortunately we do not have enough data on TENX's stock to indicate if its a good dividend stock.
Based on targets from 2 analysts, the average taret price for TENX is USD 18.00 over the next 12 months. The maximum analyst target price is USD 20 while the minimum anlayst target price is USD 16.
Unfortunately we do not have enough data on TENX's stock to indicate if its overvalued.
The last closing price of TENX's stock was USD 5.56.
The most recent market capitalization for TENX is USD 0.03B.
Based on targets from 2 analysts, the average taret price for TENX is projected at USD 18.00 over the next 12 months.
This means that TENX's stock price may go up by +223.74% over the next 12 months.
We can't find any ETFs which contains Tenax Therapeutics Inc's stock.
As per our most recent records Tenax Therapeutics Inc has 5 Employees.
Tenax Therapeutics Inc's registered address is 101 Glen Lennox Drive, Chapel Hill, NC, United States, 27517.
You can get more information about it from Tenax Therapeutics Inc's website at https://www.tenaxthera.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for TENX !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
